Quick Takeaways: Why It Matters? Boehringer Ingelheim’s purchase of Evax gives it a promising new way to treat common horse allergies with longer‑lasting vaccines instead of short‑term symptom relief, which could mean fewer vet visits and better outcomes for owners. If the approach works a...
Quick Takeaways: Why It Matters? With 138 horses across eight practices showing significantly better outcomes and nearly triple the odds of returning to prior performance, the data should help veterinarians justify using equicenta CTM as a convenient, regenerative alternative to harvesting...
Quick Takeaways: Why It Matters? If the science holds up, this could open a future premium category for hypoallergenic dogs and related breeding or licensing programs, creating new value in the pet biotech space while also raising major regulatory, ethical, and animal-welfare h...
Quick Takeaways: Why It Matters? By terminating the PrecisePRP arrangement with VetStem, PetVivo removes outstanding invoices, royalties and milestone overhangs from a non-core product line, which should simplify the story for investors and management while freeing attention and capital fo...
Quick Takeaways: Why It Matters? The deal strengthens Magapor’s ability to expand beyond its 60+ country footprint by adding growth capital for R&D, commercial expansion and product development in a niche but defensible livestock-reproduction category, while allowing the Mena Gericó fa...
Quick Takeaways: Why It Matters? Akston could emerge as a serious competitor in the fast-growing anti‑NGF OA segment that Zoetis currently leads with its once‑monthly monoclonal. Because Akston’s Ambifect approach stimulates sustained endogenous anti‑NGF antibody responses, AKS‑548d remain...
The US FDA’s 2025 animal health approvals highlight a transformative year for veterinary medicine, with major advances spanning companion animal therapeutics, livestock productivity, poultry health, parasitic disease management, diagnostics, oncology, and genetic innovation. The latest wav...
Quick Takeaways: Why It Matters? Elanco Ventures adds a structured, early-stage venture arm to Elanco’s strategy, giving the company a dedicated channel to access and co-develop emerging animal health technologies before they become mature competitors or acquisition targets. The ...
Quick Takeaways: Why It Matters? BiomEdit’s new patents effectively lock up its engineered Lactobacillus reuteri pvAb platform, giving it composition‑of‑matter and methods‑of‑use protection around BE‑101 and future in situ biologic payloads delivered vi...
Quick Takeaways: Why It Matters? Lenzelta gives Boehringer Ingelheim a next‑generation mastitis vaccine that fits neatly into dry‑off protocols: two intramuscular doses in late gestation deliver early‑onset immunity and up to six months...
